特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
969592

コンパニオン診断市場 - 診断の将来 (2021-2025年):資金源・アプリケーション・予測/分析・COVIDのアップデート・エグゼクティブ&コンサルタントガイド

Companion Diagnostic Markets - The Future of Diagnostics. By Funding Source and Application with Customized Forecasting/Analysis, Covid Updates, and Executive and Consultant Guides 2021-2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 426 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
コンパニオン診断市場 - 診断の将来 (2021-2025年):資金源・アプリケーション・予測/分析・COVIDのアップデート・エグゼクティブ&コンサルタントガイド
出版日: 2020年11月06日
発行: Howe Sound Research
ページ情報: 英文 426 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のコンパニオン診断市場について調査分析し、市場の定義と概要、市場動向、開発動向、主要国/地域の詳細な内訳、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

i.コンパニオン診断市場:戦略的状況分析

ii.エグゼクティブ、マーケティング、セールス、ビジネス開発スタッフのためのガイド

iii.経営コンサルタントおよび投資顧問のためのガイド

第1章 イントロダクションおよび市場定義

  • コンパニオン診断とは?
  • オーダメイド医療革命
  • 市場定義
    • 収益市場規模
  • 調査手法
  • 臨床検査に関する支出の見通し
    • 米国の臨床検査向けメディケア支出

第2章 市場概要

  • ダイナミックな市場のプレーヤー
    • 学術研究所
    • 診断テスト開発企業
    • 計装サプライヤー
    • ディストリビューターおよび試薬サプライヤー
    • 独立試験機関
    • 国公立/地域研究所
    • 病院ラボ
    • 診療所
    • 監査機関
    • 認証機関
  • オーダーメイド医療およびコンパニオン診断
    • 基本
    • 方法
    • 疾病リスク評価
    • アプリケーション
    • 診断と介入
    • 医薬品の開発と使用法
    • 呼吸プロテオミクス
    • がんゲノミクス
    • 集団検診
    • 課題
    • 規制の監視
    • 知的財産権
    • 医療費償還方針
    • 患者のプライバシーと守秘義務
  • 染色体、遺伝子およびエピジェネティクス
    • 染色体
    • 遺伝子
    • エピジェネティクス
  • がん遺伝子
    • 生殖細胞系列 vs 体細胞
    • 臨床的役割の変化
  • 業界構造が役割を果たす
    • 新しい医薬品資金調達市場
    • 規模の経済
    • 診療者
    • 医師とPOCT

第3章 市場動向

  • 成長促進要因
    • ケアのレベル
    • 免疫腫瘍学
    • 責任
    • 高齢者人口
  • 成長抑制要因
    • 知識の状態
    • 遺伝子の嵐
    • プロトコル抵抗
    • 規制と適用範囲
  • 計装と自動化
    • 市場シェアの鍵となる機器
    • バイオインフォマティクスが役割を果たす
  • 診断技術の開発
    • 次世代シーケンシングが革命を後押し
    • シングルセルゲノミクスが状況を変える
    • 薬理ゲノミクスは診断と治療を曖昧に
    • CGESテスト、すばらしい新世界
    • バイオチップ/巨大磁気抵抗ベースのアッセイ

第4章 コンパニオン診断の最近の開発

  • 最近の開発:重要性およびこのセクションの使用方法
    • これらの開発の重要性
    • このセクションの使用方法

第5章 主要企業のプロファイル

  • 10x Genomics, Inc.
  • Abbott Diagnostic
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostic
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostic
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostic
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostic
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostic
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostic
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostic
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostic
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第6章 コンパニオン診断の世界の市場

  • 世界市場の概要:国別
  • 世界市場の概要:アプリケーション別
  • 世界市場の概要:ソース別

第7章 世界のコンパニオン診断市場:アプリケーション別

  • 腫瘍学
  • 神経学
  • 心臓病学
  • その他のアプリケーション

第8章 世界のコンパニオン診断市場:資金源別

  • 医薬品
  • ベンチャー
  • 臨床
  • その他の資金

付録

図表

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Market Players by Type
  • Table 3 The Base Pairs
  • Table 4 Five Factors Driving Growth
  • Table 5 Four Factors Limiting Growth
  • Table 6 Key Diagnostic Laboratory Technology Trends
  • Table 7 Next Generation Sequencing Technologies - Speed and Cost
  • Table 8 Global Companion Diagnostic Market by Region
  • Table 9 Global Market by Application
  • Table 10 Global Market by Funding Source
  • Table 11 Oncology by Country
  • Table 12 Neurology by Country
  • Table 13 Cardiology by Country
  • Table 14 Other Application by Country
  • Table 15 Pharmaceutical by Country
  • Table 16 Venture by Country
  • Table 17 Clinical by Country
  • Table 18 Other Funding by Country
  • Table 19 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 DNA Strands and Chromosomes
  • Figure 4 Karyogram of Human Chromosomes
  • Figure 5 Size of Various Genomes
  • Figure 6 Germline vs Somatic Mutations
  • Figure 7 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 8 Percentage of World Population Over 65
  • Figure 9 Base Year Country Market Share Chart
  • Figure 10 CDx Market by Application - Base vs. Final Year
  • Figure 11 CDx Market by Application Base Year
  • Figure 12 CDx Market by Application Final Year
  • Figure 13 Application Type Share by Year
  • Figure 14 Funding Source - Base vs. Final Year
  • Figure 15 Funding Source Market Base Year
  • Figure 16 Funding Source Market Final Year
  • Figure 17 Funding Source Share by Year
  • Figure 18 Oncology Growth
  • Figure 19 Neurology Growth
  • Figure 20 Cardiology Growth
  • Figure 21 Other Application Growth
  • Figure 22 Pharmaceutical Growth
  • Figure 23 Venture Growth
  • Figure 24 Clinical Growth
  • Figure 25 Other Funding Growth
  • Figure 26 2020 Clinical Laboratory Fee Schedule
目次

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

" Companion Diagnostic Markets, the future of diagnostics. By Funding Source and Application with customized forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2021-2025" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Specific growth and market size estimates for your area of interest is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Companion Diagnostics?
  • 1.2 The Personalized Medicine Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Personalized Medicine and Companion Diagnostics
    • 2.2.1 Basics
    • 2.2.2 Method
    • 2.2.3 Disease risk assessment
    • 2.2.4 Applications
    • 2.2.5 Diagnosis and intervention
    • 2.2.5.1 Companion Diagnostics
    • 2.2.6 Drug development and usage
    • 2.2.7 Respiratory proteomics
    • 2.2.8 Cancer genomics
    • 2.2.9 Population screening
    • 2.2.10 Challenges
    • 2.2.11 Regulatory oversight
    • 2.2.12 Intellectual property rights
    • 2.2.13 Reimbursement policies
    • 2.2.14 Patient privacy and confidentiality
  • 2.3 Chromosomes, Genes and Epigenetics
    • 2.3.1 Chromosomes
    • 2.3.2 Genes
    • 2.3.3 Epigenetics
  • 2.4 Cancer Genes
    • 2.4.1 Germline vs Somatic
    • 2.4.2 Changing Clinical Role
  • 2.5 Structure of Industry Plays a Part
    • 2.5.1 New Pharmaceutical Funding Market
    • 2.5.2 Economies of Scale
    • 2.5.2.1 Hospital vs. Central Lab
    • 2.5.3 Physician Office Labs
    • 2.5.4 Physicians and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Level of Care
    • 3.1.2 Immuno-oncology
    • 3.1.3 Liability
    • 3.1.4 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 State of knowledge
    • 3.2.2 Genetic Blizzard
    • 3.2.3 Protocol Resistance
    • 3.2.4 Regulation and coverage
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies
  • Promega to Develop MSI Assay as CDx
  • HTG Molecular Q2 Revenues Drop 66 Percent
  • Guardant Health to Develop CDx for Janssen
  • Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • FDA Approval for FoundationOne®CDx
  • FDA finalizes CDx Guidance
  • QIAGEN Launches CDx Therascreen BRAF Test
  • Myriad Genetics Seeks Approval for Companion Diagnostic
  • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
  • QIAGEN Builds on Global Collaboration with Amgen
  • Foundation Medicine nabs 19th companion Dx
  • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostic
  • Myriad Wins Japanese Approval for BRACAnalysis
  • Fujitsu Improves Efficiency in Cancer Genomic Medicine
  • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
  • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
  • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
  • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
  • Universal Genetic Testing for All Breast Cancer Patients
  • Exact Sciences buys Genomic Health
  • Biodesix Highlights Pipeline and Companion Diagnostic Development
  • Multi-Gene Liquid Biopsy Breast Cancer Panel
  • New Gene Panel Identifies High Risk Prostate Cancer
  • Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • Inivata Completes £39.8M Series B Funding Round
  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
  • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • 10x Genomics, Inc.
  • Abbott Diagnostic
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostic
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostic
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostic
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostic
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostic
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostic
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostic
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostic
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for Companion Diagnostic

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Application - Overview
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Application - Base Year
    • 6.2.4 Chart - Global Market by Application - Final Year
    • 6.2.5 Chart - Global Market by Application - Share by Year
  • 6.3 Global Market Funding Source - Overview
    • 6.3.1 Table - Global Market by Funding Source
    • 6.3.2 Chart - Global Market Funding Source - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market Funding Source - Base Year
    • 6.3.4 Chart - Global Market Funding Source - Final Year
    • 6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application

  • 7.1 Oncology
    • 7.1.1 Table Oncology - by Country
    • 7.1.2 Chart - Oncology Growth
  • 7.2 Neurology
    • 7.2.1 Table Neurology - by Country
    • 7.2.2 Chart - Neurology Growth
  • 7.3 Cardiology
    • 7.3.1 Table Cardiology - by Country
    • 7.3.2 Chart - Cardiology Growth
  • 7.4 Other Application
    • 7.4.1 Table Other Application - by Country
    • 7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source

  • 8.1 Global Market Pharmaceutical
    • 8.1.1 Table Pharmaceutical - by Country
    • 8.1.2 Chart - Pharmaceutical Growth
  • 8.2 Global Market Venture
    • 8.2.1 Table Venture - by Country
    • 8.2.2 Chart - Venture Growth
  • 8.3 Global Market Clinical
    • 8.3.1 Table Clinical - by Country
    • 8.3.2 Chart - Clinical Growth
  • 8.4 Global Market Other Funding
    • 8.4.1 Table Other Funding - by Country
    • 8.4.2 Chart - Other Funding Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. Pharmacogenomic Biomarkers in Drug Labeling
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.